Chemistry:Alloisoleucine
From HandWiki
![]() | |
Identifiers | |
---|---|
3D model (JSmol)
|
|
1721791 | |
ChEBI |
|
ChEMBL |
|
ChemSpider | |
DrugBank |
|
EC Number |
|
PubChem CID
|
|
UNII |
|
| |
| |
Properties | |
Appearance | white solid |
Melting point | 285 °C (545 °F; 558 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Infobox references | |
Alloisoleucine is an amino acid with the formula CH
3CH
2CH(CH
3)CH(NH
2)CO
2H. It exists as two enantiomers, of which the L derivative occurs naturally. L-Alloisoleucine occurs in healthy serum in only trace amounts, except for individuals suffering from maple syrup urine disease.[1]
Structure
Together with valine, leucine, and isoleucine, alloisoleucine is classified as a branched chain amino acid (BCAA). It is the rarist of the four.
L-Alloisoleucine is a diastereomer of the proteogenic amino acid L-isoleucine. The stereochemistry of the isobutyl group differs for L-alloisoleucine and L-isoleucine.
![]() ![]() |
l-isoleucine (2S,3S) and d-isoleucine (2R,3R) |
![]() ![]() |
l-alloisoleucine (2S,3R) and d-alloisoleucine (2R,3S) |
Role in biosynthesis
L-allo-isoleucine is a precursor to coronamic acid, which is a constituent of the phytotoxin coronatine, produced by Pseudomonas syringae.[2]
References
- ↑ Schadewaldt, Peter; Bodner-Leidecker, Annette; Hammen, Hans-Werner; Wendel, Udo (2000). "Formation of L-Alloisoleucine in Vivo : An L-[13C]Isoleucine Study in Man". Pediatric Research 47 (2): 271–277. doi:10.1203/00006450-200002000-00020. PMID 10674358.
- ↑ Vaillancourt, Frédéric H.; Yeh, Ellen; Vosburg, David A.; O'Connor, Sarah E.; Walsh, Christopher T. (August 2005). "Cryptic chlorination by a non-haem iron enzyme during cyclopropyl amino acid biosynthesis" (in en). Nature 436 (7054): 1191–1194. doi:10.1038/nature03797. ISSN 1476-4687. PMID 16121186. Bibcode: 2005Natur.436.1191V. https://www.nature.com/articles/nature03797.
![]() | Original source: https://en.wikipedia.org/wiki/Alloisoleucine.
Read more |